- Home
- HLP vs RPTX Comparison
HLP vs RPTX Comparison
Compare HLP & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | RPTX |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.7M | 92.4M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HLP | RPTX |
|---|---|---|
| Price | $1.20 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 80.0K | ★ 530.7K |
| Earning Date | 05-15-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $16,731,357.00 | $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | $56.36 | ★ N/A |
| Revenue Growth | ★ 19.13 | N/A |
| 52 Week Low | $0.61 | $0.89 |
| 52 Week High | $1.82 | $2.30 |
Technical Indicators
Market Signals| Indicator | HLP | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 60.89 |
| Support Level | $1.04 | $2.15 |
| Resistance Level | $1.31 | $2.27 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 22.73 | 68.75 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.